Diabetes 53:2893-2900, 2004
© 2004 by the American Diabetes Association, Inc.
Hepatic Lipase mRNA, Protein, and Plasma Enzyme Activity Is Increased in the Insulin-Resistant, Fructose-Fed Syrian Golden Hamster and Is Partially Normalized by the Insulin Sensitizer Rosiglitazone
Gary F. Lewis1,
Susan Murdoch2,
Kristine Uffelman1,
Mark Naples3,
Linda Szeto1,
Alegria Albers2,
Khosrow Adeli3, and
John D. Brunzell2
1 Department of Medicine and Physiology, Division of Endocrinology and Metabolism, University of Toronto, Toronto, Ontario, Canada
2 Department of Medicine, Division of Metabolism, Endocrinology and Nutrition, University of Washington, Seattle, Washington
3 Department of Laboratory Medicine and Pathobiology, Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada
Postheparin plasma hepatic lipase (HL) activity has been shown to correlate with features of the metabolic syndrome and type 2 diabetes in humans. We examined HL postheparin plasma enzyme activity, hepatocyte mRNA, and protein mass in the insulin-resistant, fructose-fed Syrian golden hamster, and the response of the insulin-sensitizing peroxisome proliferatoractivated receptor- agonist rosiglitazone. Male Syrian golden hamsters were treated for 5 weeks with 1) normal diet (DIET group), 2) 60% fructose diet (FRUC group), or 3) 60% fructose and rosiglitazone (20 mmol · kg1 · day1) (FRUC+RSG group). Hepatocyte HL mRNA, protein mass, and postheparin plasma HL activity were increased in FRUC compared with DIET hamsters. FRUC+RSG hamsters had partial normalization of HL mRNA, mass, and activity. There was a shift in the size of LDL particles from large to small in FRUC animals and a shift back to large LDL size in FRUC+RSG. This is the first demonstration that HL hepatocyte mRNA, mass, and plasma enzymatic activity increase concomitantly with induction of an insulin-resistant state and can be partially normalized by treatment with an insulin sensitizer. The increase in HL in insulin-resistant states may play an important role in the typical dyslipidemia of these conditions, and reduction of HL could explain some of the beneficial effects of insulin sensitizers on the plasma lipid profile.
Address correspondence and reprint requests to Gary F. Lewis, Toronto General Hospital, 200 Elizabeth St., EN11-229, Toronto, Ontario, Canada M5G 2C4. E-mail: gary.lewis{at}uhn.on.ca

CiteULike Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
S. Rashid, B. W. Patterson, and G. F. Lewis
Thematic review series: Patient-Oriented Research. What have we learned about HDL metabolism from kinetics studies in humans?
J. Lipid Res.,
August 1, 2006;
47(8):
1631 - 1642.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. G. Schneider, M. von Eynatten, S. Schiekofer, P. P. Nawroth, and K. A. Dugi
Low Plasma Adiponectin Levels Are Associated With Increased Hepatic Lipase Activity In Vivo
Diabetes Care,
September 1, 2005;
28(9):
2181 - 2186.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. F. Lewis and D. J. Rader
New Insights Into the Regulation of HDL Metabolism and Reverse Cholesterol Transport
Circ. Res.,
June 24, 2005;
96(12):
1221 - 1232.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2004 by the American Diabetes Association.
|
|
| |
|